Replies to post #445245 on NorthWest Biotherapeutics Inc (NWBO)

[dmb2]

pgsd, thx for these research pieces.

GBM is so cancer educational. I am not schooled enough in other cancers to understand how much of GBM cellular activity applies to other cancers or how much cellular activity is generic to all cancers, if any.

I wonder if anyone on this board can comment on this?

GLTA

[DocLee]

A question.
In the linked article in "Frontiersin.org", the therapy immediately following DCVax-L (ref. 83) was using an agent called "Audencel" (ref. 84). This was also an autologous dendritic cell vaccine primed with lysed GBM tissue but it failed. It's failure was reported in Cancers (Basel) (2018) 10:372–86. doi: 10.3390/cancers10100372, but I cannot access the full artcle, only the abstract.
Can anybody tell me what differences there were in the production of the failed treatment, "Audencel", and the production of DCVax-L?

Many thanks.